These results suggest the possibility that a combination therapy involving conventional chemotherapy to debulk the majority of the more differentiated tumor cells together with an IL-6 pathway-inhibiting agent to ablate cancer stem cells might be beneficial for patients with HNSCC. The gene discussed is IL6; the disease is neoplasm.